Chapter 5 The immunopathogenesis of myasthenia gravis

Handbook of Clinical Neurology

Volumn 91, Issue , 2008, Pages 169-212

  Sommer, Norbert ^a,b   Tackenberg, Björn ^a   Hohlfeld, Reinhard ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Christophsbad ^*  (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANTIGEN PRESENTING CELL; BIOLOGICAL MODEL; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; MYASTHENIA GRAVIS; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTIGEN-PRESENTING CELLS; HUMANS; IMMUNE SYSTEM; MODELS, IMMUNOLOGICAL; MYASTHENIA GRAVIS;

EID: 66049130289     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)01505-9     Document Type: Review

References (476)

1. Aarli J.A., Lefvert A.K., and Tonder O. Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination. J Neuroimmunol 1 (1981) 421-427
2. Abbas A.K., Lohr J., Knoechel B., et al. T cell tolerance and autoimmunity. Autoimmun Rev 3 (2004) 471-475
3. Adikari S.B., Lian H., Link H., et al. Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol 138 (2004) 230-236
4. Afzali B., Lombardi G., Lechler R.I., et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 148 (2007) 32-46
5. Agafonov B.V., Tsuman V.G., Shagal D.I., et al. Twin studies of myasthenia. Zh Nevrol Psikhiatr Im S S Korsakova 97 (1997) 18-21 [article in Russian]
6. Agius M.A., Zhu S., Kirvan C.A., et al. Rapsyn antibodies in myasthenia gravis. Ann N Y Acad Sci 841 (1998) 516-521
7. Ahlberg R., Yi Q., Pirskanen R., et al. Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. Neurology 44 (1994) 1732-1737
8. Aissaoui A., Klingel-Schmitt I., Couderc J., et al. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Ann Neurol 46 (1999) 559-567
9. Allen N., Kissel P., Pietrasiuk D., et al. Myasthenia gravis in monozygotic twins. Clinical follow-up nine years after thymectomy. Arch Neurol 41 (1984) 994-996
10. Allen P.M. Peptides in positive and negative selection. Cell 76 (1994) 593-596
11. Altomare G., Capella G.L., and Frigerio E. Sweet syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinate. Haematologica 81 (1996) 54-58
12. Anderson M.S., Venanzi E.S., Chen Z., et al. The cellular mechanism of Aire control of T cell tolerance. Immunity 23 (2005) 227-239
13. Andrews P.I., Massey J.M., and Sanders D.B. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology 43 (1993) 977-982
14. Andrews P.I., Massey J.M., Howard Jr. J.F., et al. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 44 (1994) 1208-1214
15. Ansevin C.S., and Agamanolis D.P. Rippling muscles and myasthenia gravis with rippling muscles. Arch Neurol 53 (1996) 197-199
16. Aricha R., Feferman T., Souroujon M.C., et al. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB J 20 (2006) 374-376
17. Aruna B.V., Ben-David H., Sela M., et al. A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis. Immunology 118 (2006) 413-424
18. Ashizawa T., and Appel S.H. Complement-dependent lysis of cultured rat myotubes by myasthenic immunoglobulins. Neurology 35 (1985) 1748-1753
19. Ashton-Rickardt P.G., and Tonegawa S. A differential-avidity model for T-cell selection. Immunol Today 15 (1994) 362-366
20. Aspinall R., and Andrew D. Thymic involution in aging. J Clin Immunol 20 (2000) 250-256
21. Avni I., Sharabi Y., Sadeh M., et al. Eosinophilia, myositis, and myasthenia gravis associated with a thymoma. Muscle Nerve 34 (2006) 242-245
22. Baggi F., Nicolle M., Vincent A., et al. Presentation of endogenous acetylcholine receptor epitope by an MHC class II-transfected human muscle cell line to a specific CD4+ T cell clone from a myasthenia gravis patient. J Neuroimmunol 46 (1993) 57-65
23. Bailey R.O., Dunn H.G., Rubin A.M., et al. Myasthenia gravis with thymoma and pure red blood cell aplasia. Am J Clin Pathol 89 (1988) 687-693
24. Balandina A., Lecart S., Dartevelle P., et al. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105 (2005) 735-741
25. Balasa B., and Sarvetnick N. Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis. Immunol Today 21 (2000) 19-23
26. Baron R.L., Lee J.K.T., Sagel S.S., et al. Computed tomography of the normal thymus. Radiology 142 (1982) 121-125
27. Bartoccioni E., Scuderi F., Minicuci G.M., et al. Anti-musk antibodies: correlation with myasthenia gravis severity. Neurology 67 (2006) 505-507
28. Barton G.M., and Rudensky A.Y. Evaluating peptide repertoires within the context of thymocyte development. Semin Immunol 11 (1999) 417-422
29. Batocchi A.P., Majolini L., Evoli A., et al. Course and treatment of myasthenia gravis during pregnancy. Neurology 52 (1999) 447-452
30. Beeson D., Jacobson L., Newsom-Davis J., et al. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology 47 (1996) 1552-1555
31. Beeson D., Bond A.P., Corlett L., et al. Thymus, thymoma, and specific T cells in myasthenia gravis. Ann N Y Acad Sci 841 (1998) 371-387
32. Ben-David H., Sela M., and Mozes E. Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis. Proc Nat Acad Sci USA 102 (2005) 2028-2033
33. Ben-David H., Aruna B.V., Seger R., et al. A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. Proc Nat Acad Sci USA 103 (2006) 18232-18237
34. Bernasconi P., Barberis M., Baggi F., et al. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 167 (2005) 129-139
35. Beroukhim R., and Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron 15 (1995) 323-331
36. Berrih-Aknin S., Cohen-Kaminsky S., Lepage V., et al. T-cell antigenic sites involved in myasthenia gravis: correlations with antibody titre and disease severity. J Autoimmun 4 (1991) 137-153
37. Besinger U.A., Toyka K.V., Homberg M., et al. Myasthenia gravis: long-term correlation of binding and bungarotoxin-blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33 (1983) 1316-1321
38. Biesecker G., and Gomez C.M. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 142 (1989) 2654-2659
39. Blaes F., Beeson D., Plested P., et al. Igg from "seronegative" myasthenia gravis patients binds to a muscle cell line, te671, but not to human acetylcholine receptor. Ann Neurol 47 (2000) 504-510
40. Blalock A. Thymectomy in the treatment of myasthenia gravis: report of twenty cases. J Thorac Surg 13 (1944) 316
41. Bolger G.B., Sullivan K.M., Spence A.M., et al. Myasthenia gravis after allogeneic bone marrow transplantation: relationship to chronic graft-versus-host disease. Neurology 36 (1986) 1087-1091
42. Boneva N., Frenkian-Cuvelier M., Bidault J., et al. Major pathogenic effects of anti-musk antibodies in myasthenia gravis. J Neuroimmunol 177 (2006) 119-131
43. Bornemann A., and Kirchner T. An immuno-electron-microscopic study of human thymic b cells. Cell Tissue Res 284 (1996) 481-487
44. Brocke S., Brautbar C., Steinman L., et al. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to hla class ii genes. J Clin Invest 82 (1988) 1894-1900
45. Brownlow S., Webster R., Croxen R., et al. Acetylcholine receptor delta subunit mutations underlie a fast-channel myasthenic syndrome and arthrogryposis multiplex congenita. J Clin Invest 108 (2001) 125-130
46. Buckley C., Douek D., Newsom-Davis J., et al. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 50 (2001) 64-72
47. Budavari A.I., Whitaker M.D., and Helmers R.A. Thymic hyperplasia presenting as anterior mediastinal mass in 2 patients with Graves disease. Mayo Clin Proc 77 (2002) 495-499
48. Bundey S. A genetic study of infantile and juvenile myasthenia gravis. J Neurol Neurosurg Psychiatry 35 (1972) 41-51
49. Burnet F.M., and Holmes M.C. Thymus lesions in an auto-immune disease of mice. Nature 194 (1962) 146
50. Burns T.M., Juel V.C., Sanders D.B., et al. Neuroendocrine lung tumors and disorders of the neuromuscular junction. Neurology 52 (1999) 1490-1491
51. Buzzard E.F. The clinical history and post-mortem examination of five cases of myasthenia gravis. Brain 28 (1906) 438-483
52. Carlsson B., Wallin J., Pirskanen R., et al. Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics 31 (1990) 285-290
53. Castleman B. The pathology of thymus gland in myasthenia gravis. Ann N Y Acad Sci 135 (1966) 496-503
54. Castleman B., and Norris E.H. The pathology of the thymus gland in myasthenia gravis. Medicine 28 (1949) 27-58
55. Childs L.A., Harrison R., and Lunt G.G. Complement-mediated muscle damage produced by myasthenic sera. Ann N Y Acad Sci 505 (1987) 180-193
56. Chiu H.C., Hsieh R.P., Hsieh K.H., et al. Association of HLA-DRw9 with myasthenia gravis in Chinese. J Immunogenet 14 (1987) 203-207
57. Chiu H.C., de Lange G.G., Willcox N., et al. Immunoglobulin allotypes in caucasian and Chinese myasthenia gravis: differences from Japanese patients. J Neurol Neurosurg Psychiatry 51 (1988) 214-217
58. Chorzelski T., Hashimoto T., Maciejewska B., et al. Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and brochiolitis obliterans. J Am Acad Dermatol 41 (1999) 393-400
59. Christadoss P. C5 gene influences the development of murine myasthenia gravis. J Immunol 140 (1988) 2589-2592
60. Christadoss P., Poussin M., and Deng C. Animal models of myasthenia gravis. Clin Immunol 94 (2000) 75-87
61. Christensen P.B., Jensen T.S., Tsiropoulos I., et al. Associated autoimmune diseases in myasthenia gravis. Acta Neurol Scand 91 (1995) 192-195
62. Christensen P.B., Jensen T.S., Tsiropoulos I., et al. Mortality and survival in myasthenia gravis: a Danish population based study. J Neurol Neurosurg Psychiatry 64 (1998) 78-83
63. Chuang W.Y., Ströbel P., Gold R., et al. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 58 (2005) 644-648
64. Cohle S.D., and Lie J.T. Myasthenia gravis-associated systemic vasculitis and myocarditis with involvement of the cardiac conducting tissue. Cardiovasc Pathol 5 (1996) 159-162
65. Colombara M., Antonini V., Riviera A.P., et al. Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. J Immunol 175 (2005) 7021-7028
66. Compston D.A., Vincent A., Newsom-Davis J., et al. HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103 (1980) 579-601
67. Conti-Fine B.M., Navaneetham D., Karachunski P.I., et al. T cell recognition of the acetylcholine receptor in myasthenia gravis. Ann N Y Acad Sci 841 (1998) 283-308
68. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin Invest 116 (2007) 2843-2854
69. Coronado R., Morrissette J., Sukhareva M., et al. Structure and function of ryanodine receptors. Am J Physiol 266 (1994) C1485-C1504
70. Cuénoud S., Feltkamp T., Fulpius B.E., et al. Antibodies to acetylcholine receptor in patients with thymoma but without myasthenia gravis. Neurology 30 (1980) 201-203
71. Dardenne M., Savino W., and Bach J.F. Thymomatous epithelial cells and skeletal muscle share a common epitope defined by a monoclonal antibody. Am J Pathol 126 (1987) 194-198
72. Deapen D., Escalante A., Weinrib L., et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35 (1992) 311-318
73. Delgado M., Munoz-Elias E.J., Gomariz R.P., et al. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells. J Neuroimmunol 96 (1999) 167-181
74. Delgado M., Leceta J., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 16 (2002) 1844-1846
75. Delgado M., Gonzalez-Rey E., and Ganea D. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J 18 (2004) 1453-1455
76. Dellisanti C.D., Yao Y., Stroud J.C., et al. Crystal structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 A resolution. Nat Neurosci 10 (2007) 953-962
77. Demaine A., Willcox N., Janer M., et al. Immunoglobulin heavy chain gene associations in myasthenia gravis: new evidence for disease heterogeneity. J Neurol 239 (1992) 53-56
78. Deng C., Goluszko E., Tuzun E., et al. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol 169 (2002) 1077-1083
79. Diaz-Manera J., Rojas-Garcia R., Gallardo E., et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat Clin Pract Neurol 3 (2007) 405-410
80. Djabiri F., Caillat-Zucman S., Gajdos P., et al. Association of the AChRα-subunit gene (CHRNA), DQA1*0101, and the DR3 haplotype in myasthenia gravis. Evidence for a three-gene disease model in a subgroup of patients. J Autoimmun 10 (1997) 407-413
81. Djabiri F., Gajdos P., Eymard B., et al. No evidence for an association of AChR β-subunit gene (CHRNB1) with myasthenia gravis. J Neuroimmunol 78 (1997) 86-89
82. Dondi E., Gajdos P., Bach J.F., et al. Association of Km3 allotype with increased serum levels of autoantibodies against muscle acetylcholine receptor in myasthenia gravis. J Neuroimmunol 51 (1994) 221-224
83. Dönmez B., Ozakbas S., Oktem M.A., et al. HLA genotypes in Turkish patients with myasthenia gravis: comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features. Hum Immunol 65 (2004) 752-757
84. Dourov N. Thymic atrophy and immune deficiency in malnutrition. Curr Top Pathol 75 (1986) 127-150
85. Drachman D.B., Adams R.N., Josifek L.F., et al. Functional acitivities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 307 (1982) 769-775
86. Drenckhahn D., von Gaudecker B., Muller-Hermelink H.K., et al. Myosin and actin containing cells in the human postnatal thymus. Ultrastructural and immunohistochemical findings in normal thymus and in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 32 (1979) 33-45
87. Duan R.S., Wang H.B., Yang J.S., et al. Anti-TNF-α antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun 19 (2002) 169-174
88. Dumas P., Archambeaud-Mouveroux F., Vallat J.M., et al. Myasthenia gravis associated with adrenocortical insufficiency. J Neurol 232 (1985) 354-356
89. Dupont B.L., and Richman D.P. Complement activation by anti-acetylcholine receptor monoclonal antibody in vivo correlates with potency of EAMG response in vivo. Ann N Y Acad Sci 505 (1987) 725-727
90. Dwyer D.S., Bradley R.J., Urquhart C.K., et al. Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients. Nature 301 (1983) 611-614
91. Eddy S., Wim R., Peter V.E., et al. Myasthenia gravis. Another autoimmune disease associated with hepatitis C virus infection. Dig Dis Sci 44 (1999) 186-189
92. Ehlers M., and Ravetch J.V. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol 28 (2007) 74-79
93. Engel A.G. Thyroid function and myasthenia gravis. Arch Neurol 4 (1961) 95-106
94. Engel A.G. Myasthenia gravis and myasthenic syndromes. In: Vinken P.J., Bruyn G.W., and Klawans H.L. (Eds). Handbook of Clinical Neurology. Myopathies (1992), Elsevier, Amsterdam, London, New York, Tokyo 391-455
95. Engel A.G., and Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 505 (1987) 326-332
96. Engel A.G., Tsujihata M., Lambert E.H., et al. Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations. J Neuropathol Exp Neurol 35 (1976) 569-587
97. Engel A.G., Tsujihata M., Lindstrom J.M., et al. The motor endplate in myasthenia gravis and in experimental autoimmune myasthenia gravis: a quantitative ultrastructural study. Ann N Y Acad Sci 274 (1976) 60-79
98. Engel A.G., Lindstrom J.M., Lambert E.H., et al. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology 27 (1977) 307-315
99. Engel A.G., Lambert E.H., and Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52 (1977) 267-280
100. Engel A.G., Sahashi K., and Fumagalli G. The immunopathology of acquired myasthenia gravis. Ann N Y Acad Sci 377 (1981) 158-174
101. Evoli A., Tonali P.A., Padua L., et al. Clinical correlates with anti-musk antibodies in generalized seronegative myasthenia gravis. Brain 126 (2003) 2304-2311
102. Farrugia M.E., Kennett R.P., Newsom-Davis J., et al. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve 33 (2006) 568-570
103. Farrugia M.E., Robson M.D., Clover L., et al. MRI and clinical studies of facial and bulbar muscle involvement in musk antibody-associated myasthenia gravis. Brain 129 (2006) 1481-1492
104. Fattorossi A., Battaglia A., Buzzonetti A., et al. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116 (2005) 134-141
105. Fazekas A., Komoly S., Bozsik B., et al. Myasthenia gravis: demonstration of membrane attack complex in muscle end-plates. Clin Neuropathol 5 (1986) 78-83
106. Feferman T., Maiti P.K., Berrih-Aknin S., et al. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol 174 (2005) 5324-5331
107. Felix N.J., Donermeyer D.L., Horvath S., et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 8 (2007) 388-397
108. Feltkamp T.E., van den Berg-Loonen P.M., Nijenhuis L.E., et al. Myasthenia gravis, autoantibodies, and HL-A antigens. Br Med J 1 (1974) 131-133
109. Fernandez-Mestre M.T., Vargas V., Montagnani S., et al. HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis. Hum Immunol 65 (2004) 54-59
110. Flores K.G., Li J., Sempowski G.D., et al. Analysis of the human thymic perivascular space during aging. J Clin Invest 104 (1999) 1031-1039
111. Frese A., Bethke F., Ludemann P., et al. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate. J Neurol 247 (2000) 713
112. Fritze D., Herrman C.J.R., Naeim F., et al. HL-A antigens in myasthenia gravis. Lancet 1 (1974) 240-242
113. Fujii Y., Monden Y., Nakahara K., et al. Antibody to acetylcholine receptor in myasthenia gravis: production by lymphocytes from thymus or thymoma. Neurology 34 (1984) 1182-1186
114. Fukui Y., Ishimoto T., Utsuyama M., et al. Positive and negative CD4+ thymocyte selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity 6 (1997) 401-410
115. Fumagalli G., Engel A.G., and Lindstrom J. Estimation of acetylcholine receptor degradation rate by external gamma counting in vivo. Mayo Clin Proc 57 (1982) 758-764
116. Fumagalli G., Engel A.G., and Lindstrom J. Ultrastructural aspects of acetylcholine receptor turnover at the normal end-plate and in autoimmune myasthenia gravis. J Neuropathol Exp Neurol 41 (1982) 567-579
117. Garchon H.J. Genetics of autoimmune myasthenia gravis, a model for antibody-mediated autoimmunity in man. J Autoimmun 21 (2003) 105-110
118. Garcia-Ramos G., Tellez-Zenteno J.F., Zapata-Zuniga M., et al. HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. Eur J Neurol 10 (2003) 707-710
119. Gattenloehner S., Vincent A., Leuschner I., et al. The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. Am J Pathol 152 (1998) 437-444
120. Gautel M., Lakey A., Barlow D.P., et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 43 (1993) 1581-1585
121. Genkins G., Mendelow H., Sobel H.J., et al. Myasthenia gravis: analysis of thirty-one consecutive post-mortem examinations. In: Viets H.R., Bruyn G.W., and Klawans H.L. (Eds). Myasthenia Gravis. Proceedings of the Second International Symposium (1961), Charles C Thomas, Springfield 519-530
122. Geuder K.I., Marx A., Witzemann V., et al. Pathogenetic significance of fetal-type acetylcholine receptors on thymic myoid cells in myasthenia gravis. Dev Immunol 2 (1992) 69-75
123. Gilhus H.B., Aarli J.A., and Skogen O.R. Fulminant myasthenia gravis and polymyositis after thymectomy for thymoma. Acta Neurol Scand 85 (1992) 63-65
124. Gilhus N.E., Pandey J.P., Gaarder P.I., et al. Immunoglobulin allotypes in myasthenia gravis patients with a thymoma. J Autoimmun 3 (1990) 299-305
125. Giraud M., Beaurain G., Yamamoto A.M., et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 57 (2001) 1555-1560
126. Giraud M., Beaurain G., Eymard B., et al. Genetic control of autoantibody expression in autoimmune myasthenia gravis: role of the self-antigen and of HLA-linked loci. Genes Immun 5 (2004) 398-404
127. Giraud M., Eymard B., Tranchant C., et al. Association of the gene encoding the delta-subunit of the muscle acetylcholine receptor (CHRND) with acquired autoimmune myasthenia gravis. Genes Immun 5 (2004) 80-83
128. Giraud M., Taubert R., Vandiedonck C., et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 448 (2007) 934-937
129. Goluszko E., Deng C., Poussin M.A., et al. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol 122 (2002) 85-93
130. Gonzalez-Rey E., Chorny A., and Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 7 (2007) 52-63
131. Grau J.M., Casademont J., Monforte R., et al. Myasthenia gravis after allogenic bone marrow transplantation: report of a case and pathogenic considerations. Bone Marrow Transplant 5 (1990) 435-437
132. Guyon T., Wakkach A., Poea S., et al. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidence for a compensatory mechanism triggered by receptor loss. J Clin Invest 102 (1998) 249-263
133. Hanisch F., Eger K., and Zierz S. Musk-antibody positive pure ocular myasthenia gravis. J Neurol 253 (2006) 659-660
134. Harcourt G.C., Sommer N., Rothbard J., et al. A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis. J Clin Invest 82 (1988) 1295-1300
135. Hawke S., Matsuo H., Nicolle M., et al. Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Immunol Today 17 (1996) 307-311
136. Hawkins B.R., Ip M.S., Lam K.S., et al. HLA antigens and acetylcholine receptor antibody in the subclassification of myasthenia gravis in Hong Kong Chinese. J Neurol Neurosurg Psychiatry 49 (1986) 316-319
137. Hawkins B.R., Yu Y.L., Wong V., et al. Possible evidence for a variant of myasthenia gravis based on HLA and acetylcholine receptor antibody in Chinese patients. Q J Med 70 (1989) 235-241
138. Hawn T.R., Wu H., Grossman J.M., et al. A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Nat Acad Sci USA 102 (2005) 10593-10597
139. Heidenreich F.R., and Vincent A. Antibodies to ion-channel proteins in thymoma with myasthenia, neuromyotonia, and peripheral neuropathy. Neurology 50 (1998) 1483-1485
140. Hemmer B., Vergelli M., Pinilla C., et al. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today 19 (1998) 163-168
141. Hemminki K., Li X., and Sundquist K. Familial risks for diseases of myoneural junction and muscle in siblings based on hospitalizations and deaths in Sweden. Twin Res Hum Genet 9 (2006) 573-579
142. Hill M., Moss P., Wordsworth P., et al. T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1: peptide complexes. J Neuroimmunol 97 (1999) 146-153
143. Hill M., Beeson D., Moss P., et al. Early-onset myasthenia gravis: a recurring t-cell epitope in the adult-specific acetylcholine receptor epsilon subunit presented by the susceptibility allele HLA-DR52a. Ann Neurol 45 (1999) 224-231
144. Hirabayashi H., Ohta M., Okumura M., et al. Appearance of thymoma 15 years after extended thymectomy for myasthenia gravis without thymoma. Eur J Cardiothorac Surg 22 (2002) 479-481
145. Hoch W., McConville J., Helms S., et al. Auto-antibodies to the receptor tyrosine kinase musk in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7 (2001) 365-368
146. Hoedemaekers A., Graus Y., Beijleveld L., et al. Macrophage infiltration at the neuromuscular junction does not contribute to AChR loss and age-related resistance to EAMG. J Neuroimmunol 75 (1997) 147-155
147. Hoff J.M., Daltveit A.K., and Gilhus N.E. Arthrogryposis multiplex congenita-a rare fetal condition caused by maternal myasthenia gravis. Acta Neurol Scand 113 S 183 (2006) 26-27
148. Hoffacker V., Schultz A., Tiesinga J.J., et al. Thymomas alter the t-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 96 (2000) 3872-3879
149. Hogquist K.A., Jameson S.C., and Bevan M.J. The ligand for positive selection of T lymphocytes in the thymus. Curr Opin Immunol 6 (1994) 273-278
150. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120 (1997) 865-916
151. Hohlfeld R., and Engel A.G. Induction of HLA-DR expression on human myoblasts with interferon-γ. Am J Pathol 136 (1990) 503-508
152. Hohlfeld R., and Wekerle H. The immunopathogenesis of myasthenia gravis. In: Engel A.G. (Ed). Myasthenia Gravis and Myasthenic Disorders (1999), Oxford University Press, Oxford 87-110
153. Hohlfeld R., Toyka K.V., Heininger K., et al. Autoimmune human t lymphocytes specific for acetylcholine receptor. Nature 319 (1984) 244-246
154. Hohlfeld R., Toyka K.V., Besinger U.A., et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 17 (1985) 238-242
155. Hohlfeld R., Kalies I., Kohleisen B., et al. Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 36 (1986) 618-621
156. Hohlfeld R., Toyka K.V., Tzartos S.J., et al. Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit. Proc Nat Acad Sci USA 84 (1987) 5379-5383
157. Hohlfeld R., Toyka K.V., Miner L.L., et al. Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis. J Clin Invest 81 (1988) 657-660
158. Horton R.M., Manfredi A.A., and Conti-Tronconi E.M. The "embryonic" gamma subunit of the nicotinic acetylcholine receptor is expressed in adult extraocular muscle. Neurology 43 (1993) 983
159. Huang D., Liu L., Noren K., et al. Genetic association of CTLA-4 to myasthenia gravis with thymoma. J Neuroimmunol 88 (1998) 192-198
160. Huang D., Pirskanen R., Hjelmstrom P., et al. Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol 81 (1998) 76-81
161. Huang D., Xia S., Zhou Y., et al. No evidence for interleukin-4 gene conferring susceptibility to myasthenia gravis. J Neuroimmunol 92 (1998) 208-211
162. Huang D.R., Zhou Y.H., Xia S.Q., et al. Markers in the promoter region of interleukin-10 (IL-10) gene in myasthenia gravis: implications of diverse effects of IL-10 in the pathogenesis of the disease. J Neuroimmunol 94 (1999) 82-87
163. Huang D., Zheng C., Giscombe R., et al. Polymorphisms at -174 and in the 3′ flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis. J Neuroimmunol 101 (1999) 197-200
164. Huang D., Giscombe R., Zhou Y., et al. Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis. J Neuroimmunol 105 (2000) 69-77
165. Hughes B.W., Moro De Casillas M.L., and Kaminski H.J. Pathophysiology of myasthenia gravis. Semin Neurol 24 (2004) 21-30
166. Hughes B.W., Kusner L.L., and Kaminski H.J. Molecular architecture of the neuromuscular junction. Muscle Nerve 33 (2006) 445-461
167. Hyttinen V., Kaprio J., Kinnunen L., et al. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes 52 (2003) 1052-1055
168. Im S.H., Barchan D., Maiti P.K., et al. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol 166 (2001) 6893-6898
169. Im S.H., Barchan D., Maiti P.K., et al. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J 15 (2001) 2140-2148
170. Inoue M., Marx A., Zettl A., et al. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 161 (2002) 1507-1513
171. Inoue M., Starostik P., Zettl A., et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 63 (2003) 3708-3715
172. Ito Y., Kanda N., Mitsui H., et al. Cutaneous manifestations of Sjogren's syndrome associated with myasthenia gravis. Br J Dermatol 141 (1999) 362-363
173. Izumi Y., Kinoshita I., Kita Y., et al. Myasthenia gravis with diffuse alopecia areata and pemphigus foliaceous. J Neurol 249 (2002) 1455-1456
174. Jacobsen M., Schweer D., Ziegler A., et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 26 (2000) 495-499
175. Jambou F., and Cohen-Kaminsky S. Immunoregulation by Vβ specific antibodies in myasthenia gravis: mining physiological T cell homeostasis for TCR specific therapy. Cell Mol Biol (Noisy-le-grand) 49 (2003) 181-192
176. Jambou F., Zhang W., Menestrier M., et al. Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis. J Clin Invest 112 (2003) 265-274
177. Janeway C.A., Travers P., Walport M., et al. Immunobiology. 6th ed. (2005), Garland Science, New York, London
178. Jermy A., Beeson D., and Vincent A. Pathogenic autoimmunity to affinity-purified mouse acetylcholine receptor induced without adjuvant in BALB/c mice. Eur J Immunol 23 (1993) 973-976
179. Jerne N.K. The generative grammar of the immune system. EMBO J 4 (1985) 847-852
180. Jha S., Xu K., Maruta T., et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 175 (2006) 107-117
181. Jiang W., Anderson M.S., Bronson R., et al. Modifier loci condition autoimmunity provoked by AIRE deficiency. J Exp Med 202 (2005) 805-815
182. Kaminski H.J., and Ruff R.L. Ocular muscle involvement by myasthenia gravis. Ann Neurol 41 (1997) 419-420
183. Kaminski H.J., Kusner L.L., and Block C.H. Expression of acetylcholine receptor isoforms at extraocular muscle endplates. Invest Ophthalmol Vis Sci 37 (1996) 345-351
184. Kao I., and Drachman D.B. Thymic muscle cells bear acetylcholine receptors: possible relation to myasthenia gravis. Science 195 (1977) 74-75
185. Kaul R., Shenoy M., Goluszko E., et al. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J Immunol 152 (1994) 3152-3157
186. Kerzin-Storrar L., Metcalfe R.A., Dyer P.A., et al. Genetic factors in myasthenia gravis: a family study. Neurology 38 (1988) 38-42
187. Kiechl S., Kohlendorfer U., Willeit J., et al. Myasthenia gravis and primary biliary cirrhosis. Acta Neurol Scand 93 (1996) 263-265
188. Kimura K., Nezu A., Kimura S., et al. A case of myasthenia gravis in childhood associated with chronic inflammatory demyelinating polyradiculoneuropathy. Neuropediatrics 29 (1998) 108-112
189. Kirchner T., Schalke B., Melms A., et al. Immunohistological patterns of non-neoplastic changes in the thymus in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 52 (1986) 237-257
190. Kirchner T., Hoppe F., Schalke B., et al. Microenvironment of thymic myoid cells in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 54 (1988) 295-302
191. Kirchner T., Schalke B., Buchwald J., et al. Well-differentiated thymic carcinoma. An organotypical low-grade carcinoma with relationship to cortical thymoma. Am J Surg Pathol 16 (1992) 1153-1169
192. Köhler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
193. Kohno T., Tsuji T., Hirayama K., et al. A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL/6 mice. Biol Pharm Bull 28 (2005) 736-739
194. Kolte L., Dreves A.M., Ersboll A.K., et al. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis 185 (2002) 1578-1585
195. Komal Kumar R.N., Patil S.A., Taly A.B., et al. Effect of D-penicillamine on neuromuscular junction in patients with Wilson disease. Neurology 63 (2004) 935-936
196. Kornstein M.J., Asher O., and Fuchs S. Acetylcholine receptor α-subunit and myogenin mRNAs in thymus and thymomas. Am J Pathol 146 (1995) 1320-1324
197. Krolick K.A., and Urso O.E. Analysis of helper-T-cell function by acetylcholine receptor-reactive cell lines of defined AChR-subunit specificity. Cell Immunol 105 (1987) 75-85
198. Kuks J.B., and Skallebaek D. Plasmapheresis in myasthenia gravis. A survey. Transfus Sci 19 (1998) 129-136
199. Lambert E.H., Lindstrom J.M., and Lennon V.A. End-plate potentials in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci 274 (1976) 300-318
200. Lanzavecchia A. Receptor-mediated antigen uptake and its effects on antigen presentation to class II-restricted T lymphocytes. Ann Rev Immunol 8 (1990) 773-794
201. Lanzavecchia A., and Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol 19 (2007) 268-274
202. Laufer T.M., Fan L., and Glimcher L.H. Self-reactive T cells selected on thymic cortical epithelium are polyclonal and are pathogenic in vivo. J Immunol 162 (1999) 5078-5084
203. Lefvert A. Differences in the interaction of acetylcholine receptor antibodies with receptor from normal, denervated and myasthenic human muscle. J Neurol Neurosurg Psychiatry 45 (1982) 70-73
204. Lefvert A.K., and Björkholm M. Antibodies against the acetylcholine receptor in hematologic disorders: implications for the development of myasthenia gravis after bone marrow grafting. N Engl J Med 317 (1987) 170
205. Lefvert A., Bergstrom K., Matell G., et al. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenic implications. J Neurol Neurosurg Psychiatry 41 (1978) 394-403
206. Lennon V.A. Myasthenia gravis: diagnosis by assay of serum antibodies. Mayo Clin Proc 57 (1982) 723-724
207. Lennon V.A., Lindstrom J.M., and Seybold M.E. Experimental autoimmune myasthenia gravis in rats and guinea pigs. J Exp Med 141 (1975) 1365-1375
208. Lennon V.A., Lindstrom J.M., and Seybold M. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci 274 (1976) 283-299
209. Lennon V.A., Seybold M.E., Lindstrom J.M., et al. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 147 (1978) 973-983
210. Levy Y.A., Afek Y., Sherer Y., et al. Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Semin Arthritis Rheum 28 (1998) 73-79
211. Ligers A., Teleshova N., Masterman T., et al. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2 (2001) 145-152
212. Limburg P.C., The T.H., Hummel-Tappel E., et al. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1: relation to clinical parameters in 250 patients. J Neurol Sci 58 (1983) 357-370
213. Lindstrom J. Is "seronegative" MG explained by autoantibodies to MuSK?. Neurology 62 (2004) 1920-1921
214. Lindstrom J., and Lambert E.H. Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis, and Eaton-Lambert syndrome. Neurology 28 (1978) 130-138
215. Lindstrom J.M., Seybold M.E., Lennon V.A., et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
216. Lindstrom J.M., Einarson B.L., Lennon V.A., et al. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental autoimmune myasthenia gravis. J Exp Med 144 (1976) 726-738
217. Lindstrom J.M., Engel A.G., Seybold M.E., et al. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 144 (1976) 739-753
218. Liston A., Lesage S., Wilson J., et al. AIRE regulates negative selection of organ-specific T cells. Nat Immunol 4 (2003) 350-354
219. Liu R., La Cava A., Bai X.F., et al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 175 (2005) 7898-7904
220. Liu R., Van Kaer L., La Cava A., et al. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol 176 (2006) 5247-5254
221. Liyanage Y., Hoch W., Beeson D., et al. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 25 (2002) 4-16
222. Lodoen M.B., and Lanier L.L. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol 18 (2006) 391-398
223. Lohr J., Knoechel B., Wang J.J., et al. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 203 (2006) 2785-2791
224. Losen M., Stassen M.H., Martinez-Martinez P., et al. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 128 (2005) 2327-2337
225. Lossos A., River Y., Eliakim A., et al. Neurologic aspects of inflammatory bowel disease. Neurology 45 (1995) 416-421
226. Luther C., Poeschel S., Varga M., et al. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol 164 (2005) 124-128
227. Machens A., Loliger C., Pichlmeier U., et al. Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol 91 (1999) 296-301
228. Mackay F., Silveira P.A., and Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 19 (2007) 327-336
229. MacLennan C., Beeson D., Buijs A.M., et al. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol 41 (1997) 423-431
230. Maiti P.K., Feferman T., Im S.H., et al. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J Neuroimmunol 152 (2004) 112-120
231. Manz R.A., Hauser A.E., Hiepe F., et al. Maintenance of serum antibody levels. Ann Rev Immunol 23 (2005) 367-386
232. Markert M.L., Alexieff M.J., Li J., et al. Postnatal thymus transplantation with immunosuppression as treatment for Digeorge syndrome. Blood 104 (2004) 2574-2581
233. Marx A., and Müller-Hermelink H.K. From basic immunobiology to the upcoming WHO-classification of tumors of the thymus. The Second Conference on Biological and Clinical Aspects of Thymic Epithelial Tumors and Related Recent Developments. Pathol Res Pract 195 (1999) 515-533
234. Marx A., Kirchner T., Greiner A., et al. Neurofilament epitopes in thymoma and antiaxonal autoantibodies in myasthenia gravis. Lancet 339 (1992) 707-708
235. Marx A., Schultz A., Wilisch A., et al. Myasthenia gravis. Verh Dtsch Ges Pathol 80 (1996) 116-126
236. Marx A., Wilisch A., Schultz A., et al. Pathogenesis of myasthenia gravis. Virchows Arch 430 (1997) 355-364
237. Marx A., Schultz A., Wilisch A., et al. Paraneoplastic autoimmunity in thymus tumors. Dev Immunol 6 (1998) 129-140
238. Marx A., Müller-Hermelink H.K., and Ströbel P. The role of thymomas in the development of myasthenia gravis. Ann N Y Acad Sci 998 (2003) 223-236
239. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 19 (1998) 395-404
240. Masters C.L., Dawkins R.L., Zilko P.J., et al. Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and antistriational antibodies. Am J Med 63 (1977) 689-694
241. Masunaga A., Arai T., Yoshitake T., et al. Reduced expression of apoptosis-related antigens in thymuses from patients with myasthenia gravis. Immunol Lett 39 (1994) 169-172
242. Mathis D., and Benoist C. A decade of AIRE. Nat Rev Immunol 7 (2007) 645-650
243. Matsuki K., Juji T., Tokunaga K., et al. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 86 (1990) 392-399
244. Matsumoto M.Y., Matsuo H., Oka T., et al. Thymic myoid cells as a myasthenogenic antigen and antigen-presenting cells. J Neuroimmunol 150 (2004) 80-87
245. Matsumoto M.Y., Matsuo H., Sakuma H., et al. CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis. J Immunol 176 (2006) 5100-5107
246. Matthews I., Sims G., Ledwidge S., et al. Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen. Lab Invest 82 (2002) 1407-1417
247. McConville J., Farrugia M.E., Beeson D., et al. Detection and characterization of musk antibodies in seronegative myasthenia gravis. Ann Neurol 55 (2004) 580-584
248. Meager A., Vincent A., Newsom-Davis J., et al. Spontaneous neutralising antibodies to interferon-α and interleukin-12 in thymoma-associated autoimmune disease. Lancet 350 (1997) 1596-1597
249. Meager A., Wadhwa M., Dilger P., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-α, interferon-ω and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 132 (2003) 128-136
250. Medzhitov R., and Janeway C.A. Innate immunity. N Engl J Med 343 (2000) 338-344
251. Meinl E., Klinkert W.E., and Wekerle H. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am J Pathol 139 (1991) 995-1008
252. Melms A., Schalke B.C., Kirchner T., et al. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest 81 (1988) 902-908
253. Melms A., Malcherek G., Gern U., et al. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the α-subunit. Ann Neurol 31 (1992) 311-318
254. Melms A., Faul C., Sommer N., et al. Myasthenia gravis after BMT: identification of patients at risk?. Bone Marrow Transplant 9 (1992) 78-79
255. Mendelow H. II. Pathology. In: Osserman K.E. (Ed). Myasthenia Gravis (1958), Grune and Stratton, New York 10-43
256. Meraouna A., Cizeron-Clairac G., Panse R.L., et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108 (2006) 432-440
257. Merlie J.P., Heinemann S., Einarson B., et al. Degradation of acetylcholine receptor in diaphragms of rats with experimental autoimmune myasthenia gravis. J Biol Chem 254 (1979) 6328-6332
258. Middleton G., and Schoch E.M. The prevalence of human thymic lymphoid follicles is lower in suicides. Virchows Arch 436 (2000) 127-130
259. Mier A.K., and Havard C.W. Diaphragmatic myasthenia in mother and child. Postgrad Med J 61 (1985) 725-727
260. Milani M., Ostlie N., Wang W., et al. T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 998 (2003) 284-307
261. Milani M., Ostlie N., Wu H., et al. CD4+ T and B cells cooperate in the immunoregulation of experimental autoimmune myasthenia gravis. J Neuroimmunol 179 (2006) 152-162
262. Miller J.F. Immunological function of the thymus. Lancet 2 (1961) 748-749
263. Miller J.F. Ruby anniversary: forty years of thymus immunology research. Nat Immunol 2 (2001) 663-664
264. Mishina M., Takai T., Imoto K., et al. Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature 321 (1986) 406-411
265. Mittag T., Massa T., and Kornfeld P. Multiple forms of antiacetylcholine receptor antibody in myasthenia gravis. Muscle Nerve 4 (1981) 16-25
266. Moiola L., Karachunski P., Protti M.P., et al. Epitopes on the β subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects. J Clin Invest 93 (1994) 1020-1028
267. Moiola L., Galbiati F., Martino G., et al. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur J Immunol 28 (1998) 2487-2497
268. Morgutti M., Conti-Tronconi B.M., Sghirlanzoni A., et al. Cellular immune response to acetylcholine receptor in myasthenia gravis. II. Thymectomy and corticosteroids. Neurology 29 (1979) 734-738
269. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 7 (1989) 145-173
270. Mossmann S., Vincent A., and Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1 (1986) 116-119
271. Moulian N., Bidault J., Planche C., et al. Two signaling pathways can increase fas expression in human thymocytes. Blood 92 (1998) 1297-1307
272. Müller-Hermelink H.K., and Marx A. Pathological aspects of malignant and benign thymic disorders. Ann Med 31 S2 (1999) 5-14
273. Müller-Hermelink H.K., and Marx A. Thymoma. Curr Opin Oncol 12 (2000) 426-433
274. Müller-Hermelink H.K., Marx A., and Marx K.T. Thymus. In: Damjanov I L.J. (Ed). Anderson's Pathology (1996), Mosby, St. Louis 1218-1243
275. Murakami M., Hosoi Y., Negishi T., et al. Thymic hyperplasia in patients with Graves' disease. Identification of thyrotropin receptors in human thymus. J Clin Invest 98 (1996) 2228-2234
276. Murphy J., and Murphy S.F. Myasthenia gravis in identical twins. Neurology 36 (1986) 78-80
277. Nagane Y., Utsugisawa K., Akutsu H., et al. Perivascular infiltrate of memory lymphocytes and mature dendritic cells in MG thymomas. Neurology 65 (2005) 770-772
278. Nagvekar N., Moody A.M., Moss P., et al. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 101 (1998) 2268-2277
279. Nagvekar N., Jacobson L.W., Willcox N., et al. Epitopes expressed in myasthenia gravis (MG) thymomas are not recognized by patients' T cells or autoantibodies. Clin Exp Immunol 112 (1998) 17-20
280. Nakano S., and Engel A.G. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 43 (1993) 1167-1172
281. Nakao Y., Matsumoto H., Miyazaki T., et al. Gm allotypes in myasthenia gravis. Lancet 1 (1980) 677-680
282. Namba T., Brunner N.G., Brown S.B., et al. Familial myasthenia gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families. Arch Neurol 25 (1971) 49-60
283. Namba T., Brunner N.G., and Grob D. Idiopathic giant cell polymyositis. Archives of Neurology 31 (1974) 27-30
284. Nath A., Kerman R.H., Novak I.S., et al. Immune studies in human immunodeficiency virus infection with myasthenia gravis: a case report. Neurology 40 (1990) 581-583
285. Navaneetham D., Penn A.S., Howard Jr. J.F., et al. Human thymuses express incomplete sets of muscle acetylcholine receptor subunit transcripts that seldom include the δ subunit. Muscle Nerve 24 (2001) 203-210
286. Nenninger R., Schultz A., Hoffacker V., et al. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest 78 (1998) 743-753
287. Neufert C., Becker C., Wirtz S., et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol 37 (2007) 1809-1816
288. Newsom-Davis J., Willcox N., Schluep M., et al. Immunological heterogeneity and cellular mechanisms in myasthenia gravis. Ann N Y Acad Sci 505 (1987) 12-26
289. Newsom-Davis J., Leys K., Vincent A., et al. Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients. J Neurol Neurosurg Psychiatry 54 (1991) 452-453
290. Newsom-Davis J., Buckley C., Clover L., et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci 998 (2003) 202-210
291. Nicolle M.W. Pseudo-myasthenia gravis and thymic hyperplasia in Graves' disease. Can J Neurol Sci 26 (1999) 201-203
292. Nieto I.P., Robledo J.P., Pajuelo M.C., et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thorac Surg 67 (1999) 1568-1571
293. Niks E.H., Kuks J.B., Roep B.O., et al. Strong association of musk antibody-positive myasthenia gravis and hla-dr 14-dq5. Neurology 66 (2006) 1772-1774
294. Niks E.H., Kuks J.B.M., and Verschuuren J.J.G.M. Epidemiology of myasthenia gravis with anti-musk antibodies in the Netherlands. J Neurol Neurosurg Psychiatry 78 (2007) 417-418
295. Noda M., Takahashi H., Tanabe T., et al. Structural homology of Torpedo californica acetylcholine receptor subunits. Nature 302 (1983) 528-532
296. Oda K., Goto I., Kuriowa Y., et al. Myasthenia gravis: antibodies to acetylcholine receptor with human and rat antigens. Neurology 30 (1980) 543-546
297. Ohta K., Shigemoto K., Kubo S., et al. MuSK antibodies in AChR ab-seropositive MG vs. AChR ab-seronegative MG. Neurology 62 (2004) 2132-2133
298. Olmos P., A'Hern R., Heaton D.A., et al. The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins. Diabetologia 31 (1988) 747-750
299. Onodera J., Nakamura S., Nagano I., et al. Upregulation of Bcl-2 protein in the myasthenic thymus. Ann Neurol 39 (1996) 521-528
300. Oosterhuis H.J.G.H., Limburg P.C., Hummel-Tappel E., et al. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci 58 (1983) 371-385
301. Oshima M., Ashizawa T., Pollack M.S., et al. Autoimmune T cell recognition of human acetylcholine receptor: the sites of T cell recognition in myasthenia gravis on the extracellular part of the alpha subunit. Eur J Immunol 20 (1990) 2563-2569
302. Oshima M., Ohtani M., Deitiker P.R., et al. Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients. Autoimmunity 38 (2005) 161-169
303. Oshima M., Deitiker P.R., Mosier D.R., et al. Responses in vitro of peripheral blood lymphocytes from patients with myasthenia gravis to stimulation with human acetylcholine receptor α-chain peptides: analysis in relation to age, thymic abnormality, and ethnicity. Hum Immunol 66 (2005) 32-42
304. Oshima M., Maruta T., Ohtani M., et al. Vaccination with a MHC class II peptide in alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice. J Neuroimmunol 171 (2006) 8-16
305. Osserman K.E., Tsairis P., and Weiner L.B. Myasthenia gravis and thyroid disease: clinical and immunological correlation. J Mt Sinai Hosp NY 34 (1967) 469-481
306. Ostlie N., Milani M., Wang W., et al. Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J Immunol 170 (2003) 604-612
307. Pachner A.R. Anti-acetylcholine receptor antibodies block bungarotoxin binding to native human acetylcholine receptor on the surface of te671 cells. Neurology 39 (1989) 1057-1061
308. Padua L., Tonali P., Aprile I., et al. Seronegative myasthenia gravis: comparison of neurophysiological picture in MuSK+ and MuSK- patients. Eur J Neurol 13 (2006) 273-276
309. Palmieri G., Selleri C., Montella L., et al. Thymoma followed by paroxysmal nocturnal hemoglobinuria: a unique clinical association in the context of multiorgan autoimmunity with a potential role for CD8+ T lymphocytes. Am J Hematol 81 (2006) 774-778
310. Parkin J., and Cohen B. An overview of the immune system. Lancet 357 (2001) 1777-1789
311. Pasaoglu I., Dogan R., Topcu M., et al. Multicentric angiofollicular lymph node hyperplasia associated with myasthenia gravis. Thorac Cardiovasc Surg 42 (1994) 253-256
312. Pascuzzi R.M., and Campa J.F. Lymphorrhage localized to the muscle end-plate in myasthenia gravis. Arch Pathol Lab Med 112 (1988) 934-937
313. Pascuzzi R.M., Roos K.L., and Phillips L.H. Granulomatous inflammatory myopathy associated with myasthenia gravis. A case report and review of the literature. Arch Neurol 43 (1986) 621-623
314. Patrick J., and Lindström J. Autoimmune response to acetylcholine receptor. Science 25 (1973) 871-872
315. Penn A.S., Low B.W., Jaffe I.A., et al. Drug-induced autoimmune myasthenia gravis. Ann N Y Acad Sci 841 (1998) 433-449
316. Phillips L.H., and Torner J.C. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 47 (1996) 1233-1238
317. Piddlesden S.J., Jiang S., Levin J.L., et al. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 71 (1996) 173-177
318. Pinching A.J., Peters D.K., and Newsom-Davis J. Plasma exchange in myasthenia gravis. Lancet 1 (1977) 428-429
319. Pirskanen R. Genetic associations between myasthenia gravis and the HL-A system. J Neurol Neurosurg Psychiatry 39 (1976) 23-33
320. Pirskanen R. Genetic aspects in myasthenia gravis. A family study of 264 Finnish patients. Acta Neurol Scand 56 (1977) 365-388
321. Plested P., Tang T., Spreadbury I., et al. AChr phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 59 (2002) 1682-1688
322. Poea-Guyon S., Christadoss P., Le Panse R., et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol 174 (2005) 5941-5949
323. Poussin M.A., Goluszko E., Franco J.U., et al. Role of IL-5 during primary and secondary immune response to acetylcholine receptor. J Neuroimmunol 125 (2002) 51-58
324. Poussin M.A., Tuzun E., Goluszko E., et al. B7-1 costimulatory molecule is critical for the development of experimental autoimmune myasthenia gravis. J Immunol 170 (2003) 4389-4396
325. Price P., Witt C., Allcock R., et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 167 (1999) 257-274
326. Protti M.P., Manfredi A.A., Howard Jr. J.F., et al. T cells in myasthenia gravis specific for embryonic acetylcholine receptor. Neurology 41 (1991) 1809-1814
327. Provenzano C., Arancio O., Evoli A., et al. Familial autoimmune myasthenia gravis with different pathogenetic antibodies. J Neurol Neurosurg Psychiatry 51 (1988) 1228-1230
328. Ragheb S., Mohamed M., and Lisak R.P. Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the ε{lunate}-subunit of the acetylcholine receptor. J Neuroimmunol 159 (2005) 137-145
329. Raju R., Spack E.G., and David C.S. Acetylcholine receptor peptide recognition in HLA DR3-transgenic mice: in vivo responses correlate with MHC-peptide binding. J Immunol 167 (2001) 1118-1124
330. Rasheed A.U., Rahn H.P., Sallusto F., et al. Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. Eur J Immunol 36 (2006) 1892-1903
331. Riemersma S., Vincent A., Beeson D., et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 98 (1996) 2358-2363
332. Robey E., and Fowlkes B.J. Selective events in t cell development. Ann Rev Immunol 12 (1994) 675-705
333. Romagnani S. Regulation of the T cell response. Clin Exp Allergy 36 (2006) 1357-1366
334. Romi F., Skeie G.O., Gilhus N.E., et al. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 62 (2005) 442-446
335. Rosai J. Histological Typing of Tumours of the Thymus (1999), Springer-Verlag, Berlin, Heidelberg
336. Rostedt Punga A., Ahlqvist K., Bartoccioni E., et al. Neurophysiological and mitochondrial abnormalities in musk antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 117 (2006) 1434-1443
337. Rostedt Punga A., Flink R., Askmark H., et al. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for musk antibody. Muscle Nerve 34 (2006) 111-115
338. Rowen L., Koop B.F., and Hood L. The complete 685-kilobase DNA sequence of the human β T cell receptor locus. Science 272 (1996) 1755-1762
339. Rowland L.P., Hoefer P.F., Aranow Jr. H., et al. Fatalities in myasthenia gravis. A review of 39 cases with 26 autopsy reports. Neurology 6 (1956) 307-326
340. Roxanis I., Micklem K., McConville J., et al. Thymic myoid cells and germinal center formation in myasthenia gravis: possible roles in pathogenesis. J Neuroimmunol 125 (2002) 185-197
341. Sahashi K., Engel A.G., Lambert E.H., et al. Ultrastructural localization of the terminal and lytic ninth complement component (c9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 39 (1980) 160-172
342. Saito R., Onodera H., Tago H., et al. Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients. J Neuroimmunol 170 (2005) 172-178
343. Saka E., Topcuoglu M.A., Akkaya B., et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 65 (2005) 782-783
344. Salmon A.M., Bruand C., Cardona A., et al. An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. J Clin Invest 101 (1998) 2340-2350
345. Salvetti M., Jung S., Chang S.F., et al. Acetylcholine receptor-specific T-lymphocyte clones in the normal human immune repertoire: target epitopes, HLA restriction, and membrane phenotypes. Ann Neurol 29 (1991) 508-516
346. Sato T., and Tamaoki N. Myoid cells in the human thymus and thymoma revealed by three different immunohistochemical markers for striated muscle. Acta Pathol Jpn 39 (1989) 509-519
347. Scadding G.K., Vincent A., Newsom-Davis J., et al. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 31 (1981) 935-943
348. Scarpino S., Di Napoli A., Stoppacciaro A., et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 149 (2007) 504-512
349. Schluep M., Willcox N., Vincent A., et al. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 22 (1987) 212-222
350. Schluep M., Willcox N., Ritter M.A., et al. Myasthenia gravis thymus: clinical, histological and culture correlations. J Autoimmun 1 (1988) 445-467
351. Schönbeck S., Padberg F., Hohlfeld R., et al. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis. J Clin Invest 90 (1992) 245-250
352. Schultz A., Hoffacker V., Wilisch A., et al. Neurofilament is an autoantigenic determinant in myasthenia gravis. Ann Neurol 46 (1999) 167-175
353. Schumacher E., and Roth W. Thymektomie bei einem fall von morbus basedowi mit myasthenie. Mitt Grenzgeb Med Chir 25 (1912) 746-765
354. Schumm F., Fateh-Moghadam A., and Dichgans J. Correlation between serum-anti-acetylcholine receptor antibody levels and clinical state under immunosuppressive therapy in myasthenia gravis. Eur Arch Psychiatry Neurol Sci 234 (1984) 224-230
355. Schumm F., Wiethölter H., Fateh-Moghadam A., et al. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry 48 (1985) 332-337
356. Sciamanna M.A., Griesmann G.E., Williams C.L., et al. Nicotinic acetylcholine receptors of muscle and neuronal (alpha7) types coexpressed in a small cell lung carcinoma. J Neurochem 69 (1997) 2302-2311
357. Scott B.G., Yang H., Tuzun E., et al. ICOS is essential for the development of experimental autoimmune myasthenia gravis. J Neuroimmunol 153 (2004) 16-25
358. Seifert R., and Christ B. On the differentiation and origin of myoid cells in the avian thymus. Anat Embryol 181 (1990) 287-298
359. Selcen D., Fukuda T., Shen X.M., et al. Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 62 (2004) 1945-1950
360. Sempowski G.D., Hale L.P., Sundy J.S., et al. Leukemia inhibitory factor, oncostatin m, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy. J Immunol 164 (2000) 2180-2187
361. Seybold M.E. Diagnosis of myasthenia gravis. In: Engel A.G. (Ed). Myasthenia Gravis and Myasthenic Disorders (1999), Oxford University Press, New York 167-201
362. Sheng J.R., Li L., Ganesh B.B., et al. Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. J Immunol 177 (2006) 5296-5306
363. Shi F.D., Wang H.B., Li H., et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 1 (2000) 245-251
364. Shimizu H., Kataoka H., Kawahara M., et al. Interferon causes no myasthenia in a seropositive patient with multiple sclerosis. Clin Neurol Neurosurg 109 (2007) 277-278
365. Shinomiya N., Nomura Y., and Segawa M. A variant of childhood-onset myasthenia gravis: HLA typing and clinical characteristics in Japan. Clin Immunol 110 (2004) 154-158
366. Shiono H., Roxanis I., Zhang W., et al. Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann N Y Acad Sci 998 (2003) 237-256
367. Shiraishi H., Motomura M., Yoshimura T., et al. Acetylcholine receptors loss and postsynaptic damage in musk antibody-positive myasthenia gravis. Ann Neurol 57 (2005) 289-293
368. Silman A.J., MacGregor A.J., Thomson W., et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. British J Rheumatol 32 (1993) 903-907
369. Simpson I.A. Myasthenia gravis: a new hypothesis. Scott Med J 5 (1960) 419-436
370. Slater C.R., Lyons P.R., Walls T.J., et al. Structure and function of neuromuscular junctions in the vastus lateralis of man. Brain 115 (1992) 451-478
371. Smith C.I., Grubb R., Hammarstrom L., et al. Gm allotypes in Swedish myasthenia gravis patients. J Immunogenet 10 (1983) 1-9
372. Smith C.I., Grubb R., Hammarstrom L., et al. Gm allotypes in Finnish myasthenia gravis patients. Neurology 34 (1984) 1604-1605
373. Smith K.Y., Valdez H., Landay A., et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of Zidovudine, Lamivudine, and Ritonavir therapy. J Infect Dis 181 (2000) 141-147
374. Somer H., Müller K., and Kinnunen E. Myasthenia gravis associated with multiple sclerosis. Epidemiological survey and immunological findings. J Neurol Sci 89 (1989) 37-48
375. Sommer N., Willcox N., Harcourt G.C., et al. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive t cells. Ann Neurol 28 (1990) 312-319
376. Sommer N., Harcourt G.C., Willcox N., et al. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 41 (1991) 1270-1276
377. Sommer N., Melms A., Weller M., et al. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol 84 (1993) 309-333
378. Somnier F.E. Exacerbation of myasthenia gravis after removal of thymomas. Acta Neurol Scand 90 (1994) 56-66
379. Somnier F.E. Increasing incidence of late-onset anti-AChr antibody-seropositive myasthenia gravis. Neurology 65 (2005) 928-930
380. Somnier F.E., and Engel P.J. The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999. Neurology 59 (2002) 92-98
381. Spits H. Development of ab T cells in the human thymus. Nat Rev Immunol 2 (2002) 760-772
382. Spuler S., Marx A., Kirchner T., et al. Myogenesis in thymic transplants in the severe combined immunodeficient mouse model of myasthenia gravis. Differentiation of thymic myoid cells into striated muscle. Am J Pathol 145 (1994) 766-770
383. Spuler S., Sarropoulos A., Marx A., et al. Thymoma-associated myasthenia gravis. Transplantation of thymoma and extrathymomal thymic tissue into SCID mice. Am J Pathol 148 (1996) 1359-1365
384. Stanley F.F., and Drachman D.B. Rapid degradation of "new" acetylcholine receptors at neuromuscular junctions. Science 222 (1983) 67-69
385. Stassen M.H., Meng F., Melgert E., et al. Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci. J Neuroimmunol 135 (2003) 56-61
386. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13 (2007) 139-145
387. Stickler D.E., Massey J.M., and Sanders D.B. Musk-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 116 (2005) 2065-2068
388. Strauss A.J., and Kemp Jr. P.G. Serum autoantibodies in myasthenia gravis and thymoma: selective affinity for I-bands of striated muscle as a guide to identification of antigen(s). J Immunol 99 (1967) 945-953
389. Strauss A., Seegal B.C., Hsu K.C., et al. Immunofluorescence demonstration of a muscle binding, complement-fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol Med 105 (1960) 184-191
390. Ströbel P., Helmreich M., Kalbacher H., et al. Evidence for distinct mechanisms in the shaping of the CD4 T cell repertoire in histologically distinct myasthenia gravis-associated thymomas. Dev Immunol 8 (2001) 279-290
391. Ströbel P., Rosenwald A., Beyersdorf N., et al. Selective loss of regulatory T cells in thymomas. Ann Neurol 56 (2004) 901-904
392. Ströbel P., Murumagi A., Klein R., et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 211 (2007) 563-571
393. Suzuki Y., Onodera H., Tago H., et al. Altered populations of natural killer cell and natural killer T cell subclasses in myasthenia gravis. J Neuroimmunol 167 (2005) 186-189
394. Suzuki Y., Onodera H., Tago H., et al. Altered expression of Th1-type chemokine receptor CXCR3 on CD4+ T cells in myasthenia gravis patients. J Neuroimmunol 172 (2006) 166-174
395. Szobor A. Familial myasthenia gravis: nine patients in two generations. Acta Med Hung 48 (1991) 145-149
396. Tackenberg B., Hemmer B., Oertel W.H., et al. Immunosuppressive treatment of ocular myasthenia gravis. BioDrugs 15 (2001) 369-378
397. Tackenberg B., Nitschke M., Willcox N., et al. CD45 isoform expression in autoimmune myasthenia gravis. Autoimmunity 36 (2003) 117-121
398. + B helper T cells in autoimmune myasthenia gravis. Eur J Immunol 37 (2007) 849-863
399. Takahashi H., Amagai M., Tanikawa A., et al. T helper type 2-biased natural killer cell phenotype in patients with pemphigus vulgaris. J Invest Dermatol 127 (2007) 324-330
400. Tami J.A., Urso O.E., and Krolick K.A. T cell hybridomas reactive with the acetylcholine receptor and its subunits. J Immunol 138 (1987) 732-738
401. Thangarajh M., Masterman T., Helgeland L., et al. The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J Neuroimmunol 178 (2006) 161-166
402. Thorlacius S., Mollnes T.E., Garred P., et al. Plasma exchange in myasthenia gravis: changes in serum complement and immunoglobulins. Acta Neurol Scand 78 (1988) 221-227
403. Thorlacius S., Aarli J.A., Riise T., et al. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 80 (1989) 290-295
404. Tiller T., Tsuiji M., Yurasov S., et al. Autoreactivity in human IgG+ memory B cells. Immunity 26 (2007) 205-213
405. Tindall R. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol 10 (1981) 437-447
406. Tindall R. Humoral immunity in myasthenia gravis: effects of steroids and thymectomy. Neurology 30 (1980) 554-557
407. Tindall R., Rollins J.A., Phillips J.T., et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316 (1987) 719-724
408. Tonegawa S. Somatic generation of antibody diversity. Nature 302 (1983) 575-581
409. Toyka K.V., Drachman D.B., Griffin D.E., et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 296 (1977) 125-131
410. Tsao C.Y., Mendell J.R., Lo W.D., et al. Myasthenia gravis associated with autoimmune diseases in children. J Child Neurol 15 (2000) 767-769
411. Tsuchida M., Yamato Y., Souma T., et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg 67 (1999) 1563-1567
412. Tuzun E., Li J., Saini S.S., et al. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol 182 (2007) 167-176
413. Tzartos S.J., and Lindstrom J.M. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci USA 77 (1980) 755-759
414. Tzartos S.J., Seybold M.E., and Lindstrom J. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA 70 (1982) 188-192
415. Tzartos S.J., Kokla A., Walgrave S.L., et al. Localization of the main immunogenic region of human acetylcholine receptor to residues 67-76 of the α-subunit. Proc Natl Acad Sci USA 85 (1988) 2899-2903
416. Tzartos S.J., Morel E., Efthimiadis A., et al. Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis. Clin Exp Immunol 73 (1988) 80-86
417. Tzartos S.J., Barkas T., Cung M.T., et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 163 (1998) 89-120
418. van de Velde R.L., and Friedman N.B. Thymic myoid cells and myasthenia gravis. Am J Pathol 59 (1970) 347-368
419. van de Warrenburg B.P., Hengstman G.J., Vos P.E., et al. Concomitant dermatomyositis and myasthenia gravis presenting with respiratory insufficiency. Muscle Nerve 25 (2002) 293-296
420. van der Pol W.L., Jansen M.D., Kuks J.B., et al. Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients. J Neuroimmunol 144 (2003) 143-147
421. Vandiedonck C., Beaurain G., Giraud M., et al. Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Nat Acad Sci USA 101 (2004) 15464-15469
422. Vandiedonck C., Giraud M., and Garchon H.J. Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. J Autoimmun 25 (2005) 6-11
423. Vandiedonck C., Capdevielle C., Giraud M., et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 59 (2006) 404-407
424. van Ewijk W., Shores E.W., and Singer A. Crosstalk in the mouse thymus. Immunol Today 15 (1994) 214
425. Vanhecke D., Leclercq G., Plum J., et al. Characterization of distinct stages during the differentiation of human CD69+CD3+ thymocytes and the identification of thymic emigrants. J Immunol 155 (1995) 1862-1872
426. van Meerwijk J.P., and MacDonald H.R. In vivo T-lymphocyte tolerance in the absence of thymic clonal deletion mediated by hematopoietic cells. Blood 93 (1999) 3856-3862
427. Vernet-der Garabedian B., Lacokova M., Eymard B., et al. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor. J Clin Invest 94 (1994) 555-559
428. Vincent A. Aetiological factors in development of myasthenia gravis. Adv Neuroimmunol 4 (1994) 355-371
429. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2 (2002) 797-804
430. Vincent A., and Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 49 (1982) 257-265
431. Vincent A., and Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48 (1985) 1246-1252
432. Vincent A., and Willcox N. The role of T-cells in the initiation of autoantibody responses in thymoma patients. Pathol Res Pract 195 (1999) 535-540
433. Vincent A., Newsom-Davis J., Newton P., et al. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 33 (1983) 1276-1282
434. Vincent A., Newland C., Brueton L., et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 346 (1995) 24-25
435. Vincent A., Willcox N., Hill M., et al. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol Rev 164 (1998) 157-168
436. Vincent A., Clover L., Buckley C., et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74 (2003) 1105-1108
437. Vincent A.C., McConville J., and Newsom-Davis J. Is "seronegative" MG explained by autoantibodies to MuSK?. Neurology 64 (2005) 399
438. Vinuesa C.G., Tangye S.G., Moser B., et al. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 5 (2005) 853-865
439. Voltz R., Albrich W., Hohlfeld R., et al. Anti-titin antibodies are not associated with a specific thymoma histology. J Neurol Neurosurg Psychiatry 74 (2003) 282
440. von Boehmer H. Positive selection of lymphocytes. Cell 76 (1993) 219-228
441. Wagner H. Toll meets bacterial CpG-DNA. Immunity 14 (2001) 499-502
442. Wakkach A., Poea S., Chastre E., et al. Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics. Am J Pathol 155 (1999) 1229-1240
443. Wang Z.Y., Okita D.K., Howard J.J., et al. Th1 epitope repertoire on the α subunit of human muscle acetylcholine receptor in myasthenia gravis. Neurology 48 (1997) 1643-1653
444. Wang Z.Y., Okita D.K., Howard Jr. J., et al. T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis. Neurology 50 (1998) 1045-1054
445. Wang Z.Y., Karachunski P.I., Howard Jr. J.F., et al. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes: role of CD4+ and CD8+ cells. Neurology 52 (1999) 484-497
446. Wang H.B., Shi F.D., Li H., et al. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166 (2001) 6430-6436
447. Wang X.B., Kakoulidou M., Giscombe R., et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 130 (2002) 224-232
448. Wang X.B., Kakoulidou M., Qiu Q., et al. CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. Genes Immun 3 (2002) 46-49
449. Wang W., Ostlie N.S., Conti-Fine B.M., et al. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells. J Immunol 172 (2004) 97-103
450. Wang W., Milani M., Ostlie N., et al. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-γ are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 178 (2007) 7072-7080
451. Weigert K. Pathologisch-anatomischer beitrag zur Erb'schen Krankheit. Neurol Centralbl 20 (1901) 597-601
452. Weinberg C.B., and Hall Z.W. Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc Nat Acad Sci USA 76 (1979) 504-508
453. Wekerle H., and Ketelsen U.P. Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet 1 (1977) 678-680
454. Wekerle H., Hohlfeld R., Ketelsen U.P., et al. Thymic myogenesis, T-lymphocytes and the pathogenesis of myasthenia gravis. Ann N Y Acad Sci 377 (1981) 455-476
455. Wilkins K.B., and Bulkley G. Thymectomy in the integrated management of myasthenia gravis. Adv Surg 32 (1999) 105-133
456. Willcox N. Myasthenia gravis. Curr Opin Immunol 5 (1993) 910-917
457. Willcox N., Schluep M., Sommer N., et al. Variable corticosteroid sensitivity of thymic cortex and medullary peripheral-type lympoid tissue in myasthenia gravis patients: structural and functional effects. Q J Med 271 (1989) 1071-1087
458. Williams C.L., Hay J.E., Huiatt T.W., et al. Paraneoplastic IGG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest 66 (1992) 331-336
459. Xiao B.G., Duan R.S., Link H., et al. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell Immunol 223 (2003) 63-69
460. Xu B.Y., Huang D., Pirskanen R., et al. β2-adrenergic receptor gene polymorphisms in myasthenia gravis (MG). Clin Exp Immunol 119 (2000) 156-160
461. Xu R.N., Wang J.N., Chen G.J., et al. The effect of CD3-specific monoclonal antibody on treating experimental autoimmune myasthenia gravis. Cell Mol Immunol 2 (2005) 461-465
462. Yamamoto A.M., Gajdos P., Eymard B., et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 58 (2001) 885-890
463. Yang H., Goluszko E., David C., et al. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J Clin Invest 109 (2002) 1111-1120
464. Yang H., Tuzun E., Alagappan D., et al. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J Immunol 175 (2005) 2018-2025
465. Yeh J.H., Chen W.H., Chiu H.C., et al. Low frequency of musk antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 62 (2004) 2131-2132
466. Yi Q., Ahlberg R., Pirskanen R., et al. Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells. J Neuroimmunol 50 (1994) 177-186
467. Zettl A., Ströbel P., Wagner K., et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 157 (2000) 257-266
468. Zhang Y., Schluep M., Frutiger S., et al. Immunological heterogeneity of autoreactive T lymphocytes against the nicotinic acetylcholine receptor in myasthenic patients. Eur J Immunol 20 (1990) 2577-2583
469. Zhang G.X., Ma C.G., Xiao B.G., et al. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats. Eur J Immunol 25 (1995) 1191-1198
470. Zhang G.X., Xiao B.G., Bakhiet M., et al. Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis. J Exp Med 184 (1996) 349-356
471. Zhang W., Liu J.L., Meager A., et al. Autoantibodies to IL-12 in myasthenia gravis patients with thymoma: effects on the IFN-γ responses of healthy CD4+ T cells. J Neuroimmunol 139 (2003) 102-108
472. Zhang C., Zhang J., and Tian Z. The regulatory effect of natural killer cells: do "NK-reg cells" exist?. Cell Mol Immunol 3 (2006) 241-254
473. Zhang X., Yang M., Xu J., et al. Clinical and serological study of myasthenia gravis in Hubei Province, China. J Neurol Neurosurg Psychiatry 78 (2007) 386-390
474. Zhou L., McConville J., Chaudhry V., et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 30 (2004) 55-60
475. Zisman E., Brautbar C., Sela M., et al. Binding of peptides of the human acetylcholine receptor α-subunit to HLA class ii of patients with myasthenia gravis. Hum Immunol 44 (1995) 121-130
476. Zivkovic S.A., and Medsger Jr. T.A. Myasthenia gravis and scleroderma: two cases and a review of the literature. Clin Neurol Neurosurg 109 (2007) 388-391